Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sponsors Will Need New Databases And Metrics To Determine Success Of Opioids REMS

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA sees REMS assessment as a collaborative effort and already has initiatives with other federal agencies to find ways to monitor indicators of effectiveness.
Advertisement

Related Content

FDA Wants Fast Turnaround In Assessing Opioid REMS' Effectiveness
FDA Wants Fast Turnaround In Assessing Opioid REMS' Effectiveness
Opioid REMS Could Be Linked To CME, FDA Suggests
Opioid REMS Could Be Linked To CME, FDA Suggests
REMS For Opioids, LABAs May Be Driven By PBM "Feedback" Mechanism
REMS For Opioids, LABAs May Be Driven By PBM "Feedback" Mechanism
FDA Opts For Education Over Registries in Proposed Opioids REMS
FDA Opts For Education Over Registries in Proposed Opioids REMS

Topics

Advertisement
UsernamePublicRestriction

Register

PS070832

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel